Advocacy Campaigns
CCA works to advocate for the IBD community in a range of ways:
- Lobbying governments for funding
- Providing submissions about health policy
- Raising consumer needs to researchers and industry
- Awareness campaigns
Current advocacy campaigns
State of the Nation Advocacy
We need your help to secure support from the Australian government to fund the actions specified in the IBD State of The Nation report, which will greatly improve the quality of life for people living with IBD.
Have your say in an important discussion on DNA testing legislation.
Open
Help improve the quality of life for regional Australians living with chronic inflammatory conditions
Closed 2022
Review of the National Medicines Policy
Closed October 2021.
Have your say on PBS listings for IBD Medications
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on VEDOLIZUMAB (Entyvio®) increased dosing to every 4 weeks , and RECOMBINANT ZOSTER VACCINE (Shingrix®) shingles vaccine to add listing for all 60-65 years of age, send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 21 September 2025.
| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
VEDOLIZUMAB Powder for injection 300 mg Entyvio® TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) PBS Section 100 (Highly Specialised Drugs Program) | Severe Crohn disease (CD) Moderate to severe ulcerative colitis (MSUC) | To request a change to the existing listings for vedolizumab (powder for injection 300 mg) for severe CD and MSUC, that is, additional restrictions with increased repeats to allow for dosing every 4 weeks. Authority Required |
| RECOMBINANT ZOSTER VACCINE Solution concentrate for injection, I.V. infusion 500 mg in 20 mL Shingrix® GLAXOSMITHKLINE AUSTRALIA PTY LTD (Change to existing NIP listing) | Herpes zoster virus | To request a National Immunisation Program listing with age eligibility criteria for non-Indigenous adults reduced from individuals aged 65 years of age and over to individuals aged 60 years of age and over. |
For information about the PBS meeting visit the PBAC meeting page on the PBS website.